Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Radius Health (Cambridge, MA) a clinical-stage biopharmaceutical company focused on osteoporosis and women’s health, closed a $21.4M Series C financing, bringing the total round to $91M. Participants include Brookside Capital, Saints Capital, Nordic Bioscience, Ipsen Pharma, MPM Capital, BB Biotech Ventures, The Wellcome Trust, HealthCare Ventures and Scottish Widows Investment Partnership.

Aratana Therapeutics (Kansas City, KS) a clinical-stage animal health company focused on pain, cancer, inflammation, cachexia and frailty, closed a $15.5M Series B financing. Participants include Ewing Marion Kauffman Foundation, MPM Capital, Cultivian Ventures and Avalon Ventures.

Acceleron Pharma (Cambridge, MA) is a clinical-stage biopharmaceutical company focused on protein therapeutics for anemia, cancer, Duchenne Muscular Dystrophy and bone loss diseases, closed a $30.4M Series D financing. Participants have included Advanced Technology Ventures, Avalon Ventures, Bessemer Venture Partners, Celgene, Flagship Ventures, MPM Capital, Orbimed, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock.

Verastem (Boston, MA) a development stage biopharmaceutical company focused on the treatment of cancer by targeting stem cells, closed a $32M Series B financing. Participants include Advanced Technology Ventures, Astellas Venture Management, Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital. Thanx for your patience as we catch-up.

Nevro (Menlo Park, CA) a clinical-stage medical device company focused on neuromodulation for the relief of chronic pain, closed a $58M Series B financing. Participants include Johnson & Johnson Development Corp, Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, MPM Capital and Three Arch Partners.

Theraclone Sciences (Seattle, WA) a preclinical-stage biopharmaceutical company focused on monoclonal antibodies for infectious disease and inflammation, closed a $10.6M Series B, bringing the total round to $41M. Participants include Arch Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo.

Valeritas (Bridgewater, NJ) a commercial-stage developer of a disposable insulin delivery device, closed a $150M Series C financing. Participants include Welsh, Carson, Anderson & Stowe, MPM Capital, Pitango Venture Capital, Abingworth Management, Advanced Technology Ventures, Onset Ventures, HLM Venture Partners, Agate Medical Investments, CHL Medical Partners and Kaiser Permanente Ventures.

Radius Health (Cambridge, MA) a clinical-stage biopharmaceutical company focused on osteoporosis and women’s health, closed a $66M Series C financing. Participants include Brookside Capital, Saints Capital, Nordic Bioscience, Ipsen Pharma, MPM Capital, BB Biotech Ventures, The Wellcome Trust, HealthCare Ventures and Scottish Widows Investment Partnership.

Conatus Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on liver disease and cancer, closed a $7.5M financing bring the total Series B round to $32.5M. Participants include MPM Capital.

Aratana Therapeutics (Kansas City, KS) a clinical-stage animal health company focused on pain, cancer, inflammation, cachexia and frailty, closed a $20M Series A financing. Participants include MPM Capital, Cultivian Ventures and Avalon Ventures.

Aires Pharmaceuticals (San Diego, CA) a clinical-stage pharmaceutical company focused on small molecule combination therapy for the treatment of pulmonary arterial hypertension, closed a $20M Series B financing. Participants include MPM Capital and ProQuest Investments.

Ceregene (San Diego, CA) a clinical-stage biopharmaceutical company focused adeno-associated virus vector-based gene therapy for Parkinson’s and Alzheimer’s disease, closed a $11.5M Series D financing. Participants include Hamilton BioVentures, Alta Partners, MPM Capital and Investor Growth Capital.

Verastem (Boston, MA) a development-stage biopharmaceutical company focused on stem cell oncology therapeutics, closed a $16M Series A financing. Participants include Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital.

« Previous Entries  Next Page »

to top of page...